Yamagata, Hirotaka
Kobayashi, Ayumi
Tsunedomi, Ryouichi
Seki, Tomoe
Kobayashi, Masaaki
Hagiwara, Kosuke
Chen, Chong
Uchida, Shusaku
Okada, Go
Fuchikami, Manabu
Kamishikiryo, Toshiharu
Iga, Jun-ichi
Numata, Shusuke
Kinoshita, Makoto
Kato, Takahiro A.
Hashimoto, Ryota
Nagano, Hiroaki
Okamoto, Yasumasa
Ueno, Shuichi
Ohmori, Tetsuro
Nakagawa, Shin
Funding for this research was provided by:
Japan Society for the Promotion of Science (20K07946)
Core Research for Evolutional Science and Technology
SENSHIN Medical Research Foundation
Finding-Out & Crystallization of Subliminals (FOCS) project
Japan Agency for Medical Research and Development (JP20dk0307075, JP20dk0307076h0003)
Article History
Received: 9 June 2021
Accepted: 11 August 2021
First Online: 23 August 2021
Competing interests
: HY has received research grants from Pfizer, Eisai, and MSD. SN has received honoraria and/or research grant support from Otsuka Pharmaceutical, Meiji Seika Pharma, Sumitomo Dainippon Pharma, Kyowa Pharmaceutical Industry, Shionogi, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Eisai, Tsumura, Eli Lilly, MSD, Astellas, and Pfizer. TAK has received honoraria and/or research grant support from Otsuka Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, and Pfizer. TO has received research support or speakers’ honoraria from, or has served as a consultant to Sumitomo Dainippon Pharma, Otsuka Pharmaceutical, Eisai, Pfizer, Eli Lilly, Janssen, Meiji Seika Pharma, Shionogi, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical, and Yoshitomiyakuhin. JI has received speaker’s honoraria from Otsuka Pharmaceutical, Meiji Seika Pharma, Sumitomo Dainippon Pharma, Kyowa Pharmaceutical Industry, Shionogi, Mochida Pharmaceutical, Eisai, Mylan, Sawai Pharmaceutical, Novartis Pharma, Eli Lilly, MSD, Ono Pharmaceutical, Takeda Pharmaceutical, Janssen Pharmaceutical, Sanofi, Viatris, and Yoshitomiyakuhin. The other authors declare no competing interests.